Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion
NYSE:ABBV

AbbVie Q3 2026 Earnings Date & Estimates

AbbVie logo
$286.88 +1.24 (+0.43%)
Closing price 10/26/2026 03:59 PM Eastern
Extended Trading
$287.30 +0.43 (+0.15%)
As of 04:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie is estimated to report Q3 2026 earnings on Friday, October 30, 2026, before market opens. The conference call is scheduled for 9:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
9:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from AbbVie in Q3 2026

AbbVie is expected to post earnings of $3.73 per share on revenue of $17.32 billion. In the same quarter a year earlier AbbVie reported $1.86 per share on revenue of $15.78 billion. AbbVie last reported on July 31, 2026, posting $3.65 per share and beating the $3.61 consensus estimate. AbbVie has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
$3.73
Expected Revenue
$17.32 billion
Prior-Year EPS
$1.86
Prior-Year Revenue
$15.78 billion
Expected EPS Growth
+100.5%
Expected Revenue Growth
+9.8%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
$3.65 (Beat by +$0.04)
Last Quarter Revenue
$16.99 billion
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

AbbVie Q3 2026 Earnings FAQ

AbbVie (NYSE:ABBV) is estimated to report Q3 2026 earnings on Friday, October 30, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

AbbVie's Q3 2026 earnings conference call is scheduled for Friday, October 30, 2026 at 9:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect AbbVie to post earnings of $3.73 per share for Q3 2026.

The consensus revenue estimate for AbbVie is $17.32 billion for Q3 2026.

AbbVie Earnings Headlines

AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30
October 26 at 8:00 AM  |  247wallst.comhttps://247wallst.com/investing/2026/10/26/abbvie-options-price-in-a-sudden-5-swing-what-investors-must-know-before-oct-30/
AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30
October 26 at 7:51 AM  |  247wallst.comhttps://247wallst.com/investing/2026/10/26/abbvie-options-price-in-a-sudden-5-swing-what-investors-must-know-before-oct-30/?utm_source=snapi
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.tc pixel
 |  Porter & Company (Ad)
Best Dividend Kings: October 2026
October 26 at 3:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4957389-best-dividend-kings-october-2026
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy
October 26 at 2:51 AM  |  fool.comhttps://www.fool.com/investing/2026/10/26/billionaire-ken-griffin-is-buying-this-dividend-ki/?source=marketbeat&utm_source=marketbeat&utm_medium=feed&utm_campaign=article&referring_guid=dfce328d-12ed-4b6c-82f5-d74d6cd473e7
AbbVie Stock Gets Reduced EPS Forecast from Erste Group Bank
October 26 at 1:43 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31156484
See More AbbVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like AbbVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AbbVie and other key companies, straight to your email.

About AbbVie

AbbVie (NYSE:ABBV) (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta. Through its Allergan aesthetics business, AbbVie also offers Botox Cosmetic, dermal fillers and other aesthetic treatments. The company’s earlier flagship product, Humira, was used to treat several inflammatory conditions and was one of the world’s leading pharmaceutical products before biosimilar competition began.

AbbVie became an independent company in 2013 after being separated from Abbott Laboratories. Its acquisition of Allergan, completed in 2020, expanded its presence in medical aesthetics, eye care and other specialty markets. AbbVie is headquartered in North Chicago, Illinois, and is led by Chief Executive Officer Robert A. Michael.

View AbbVie Profile
Earnings Tools